NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-121896

Registered date:

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedpsoriasis
Date of first enrollment
Target sample size
Countries of recruitment
Study typeINTERVENTIONAL
Intervention(s)Intervention name : Secukinumab INN of the intervention : Secukinumab Dosage And administration of the intervention : Subcutaneous injection Control intervention name : null

Outcome(s)

Primary OutcomePASI 75, IGA
Secondary OutcomePASI 50/75/90/100, IGA

Key inclusion & exclusion criteria

Age minimum18
Age maximum
GenderBOTH
Include criteriaCompleted the full study treatment period of 52 weeks in preceding phase III studies, and have been receiving secukinumab treatment during the maintenance phase of the preceding phase III studies, and show at least a partial response (PASI 50 or better) at Week 52 of the preceding phase III studies.
Exclude criteriaOngoing use of prohibited psoriasis or non-psoriasis treatments. Other protocol-defined inclusion/exclusion criteria may apply.

Related Information

Contact

public contact
Name Novartis Pharma K.K. Novartis Direct
Address 0120-003-293
Telephone
E-mail
Affiliation
scientific contact
Name
Address
Telephone
E-mail
Affiliation